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Introduction 
The assessment of urine flow rate dates back to the 1950’s and uroflowmetry is to date the most 
widely-used urodynamic assessment. This is in part due to its non-invasive nature, practical simplicity 
and low cost. The test is recommended as an initial objective evaluation for patients with signs and 
symptoms of lower urinary tract dysfunction by the UK National Institute for Health and Care 
Excellence (NICE)
1
, European Association of Urology (EAU)
2
, International Consultation on 
Incontinence (ICI)
3
 and American Urological Association (AUA)
4
. Although the recommendation for 
uroflowmetry is relatively undisputed, the evidence with regard to the predictive value of the test is 
not very well established.  Moreover, much of the potential information that a flowrate measurement 
contains is not very well studied and the evidence about the most studied parameter, maximum 
flowrate (Qmax), is not unambiguous.  There is for example discrepancy in practice guidelines 
regarding recommendations for the use of specific cut-off values for  Qmax in the assessment of men 
with lower urinary tract symptoms (LUTS). In a systematic review published recently only 30 studies 
could be  included from a literature search dating back to 1970, confirming a dearth of high-level 
evidence regarding the diagnostic value of uroflowmetry
5
.  The specific aim of this 2017 International 
Consultation on Incontinence Research Society (ICI-RS) think tank was to explore the question “How 
can we maximise the diagnostic utility of uroflow?”.  The areas of current knowledge are discussed 
with summaries of gaps in that knowledge.  Recommendations are then made for studies to address 
those gaps. 
 
Maximum flow rates 
One of the main problems with uroflowmetry is lack of diagnostic specificity associated with the test. 
The majority of existing work has centred on the ability of urine flow tests to provide an estimation of 
the likelihood of bladder outflow obstruction (BOO) in male patients. Outflow diameter (flow 
controlling zone) is directly related to flow rate, but also depends on intravesical pressure, and the 
parameter that has been most researched is maximum urine flowrate (Qmax). The EAU LUTS 
guidelines comment that “The diagnostic accuracy of uroflowmetry for detecting BOO varies 
considerably, and is substantially influenced by threshold values”2. The evidence for this statement 
comes from large scale studies such as the ICS BPH study
6
. The study comprised 1271 men aged 
between 45 and 88 years recruited from 12 centres in Europe, Australia, Canada, Taiwan and Japan. 
They reported that a threshold Qmax of 10 mL/s has a specificity of 70%, a PPV of 70% and a 
sensitivity of 47% for BOO as defined by invasive urodynamics. Using a higher threshold for Qmax of 
15 mL/s, the specificity was reduced to 38%, the PPV to 67% and the sensitivity increased to 
82%.Thus, as in all diagnostic tests, there is a trade-off between sensitivity and specificity as different 
(flow rate in this case) thresholds are considered. Lower Qmax thresholds are more specific to diagnose 
BOO but less sensitive and as the threshold is raised the sensitivity increases but specificity decreases.  
 
In women the relevance of maximum flowrate as a cut off is .even more difficult to establish. The 
prevalence of  female BOO is much lower than in males, but may nowadays be increasing, perhaps 
because of more interventions that can cause outflow obstruction
7,8
.  Though for most women, flow 
rates are high (above 15 – 20 mL/s)9, the specificity of a low maximum flow rate towards the cause of 
dysfunction is not fully reported in the literature.  Another group not extensively studied is healthy 
young men, who void with generally lower maximum flow rates than their female counterparts, which 
was observed especially when the voided volume is relatively low
10
. For women and for younger 
men, and to a lesser extent elderly men, therefore, very little conclusion can be drawn from 
uroflowmetry alone.  As a starting point, volume correction for interpretation of the maximum flow 
rate is recently published.
11
 
 
It is well known that maximum flow rate alone is insufficient for a specific diagnosis of LUT 
function, but there is not yet much evidence that other signs and symptoms, apart from age and gender 
, can be combined with this measurement to enhance diagnostic power. 
 
Multiple uroflow measurements 
Uroflowmetry is a clinical test that is performed by the patient. Inevitably, within-patient variability 
of the measurements made plays a role in the result. The AUA have noted in their recent guideline 
that “Clinicians should be aware that uroflow studies can be affected by the volume voided and the 
circumstances of the test” and advise that “Serial uroflowmetry measurements which are consistent, 
similar and comparable provide the most valuable information for the clinician.”4  This has led to a 
general recommendation that uroflowmetry parameters should preferably be evaluated with voided 
volume >150 mL and that serial measurements are most informative. This is supported by a study 
from Reynard et al. who concluded that the maximum Qmax of three clinic flow measurements 
provides a valuable improvement in diagnostic power over a single measurement to estimate the 
likelihood of BOO in elderly males with prostate enlargement
12
. 
 
A logical follow-on from these data has been the development of home uroflowmetry devices which 
can capture multiple voids under “usual” circumstances and thus theoretically reduce single 
observation inaccuracy. In a systematic review on the subject of home uroflowmetry recently 
published it was concluded that “the statistical benefit of averaging multiple measurements of Qmax, 
made feasible by home uroflowmetry, should translate to improved diagnostic accuracy and 
assessment of treatment outcome”13. However at the moment further studies are necessary to confirm 
this benefit, particularly to examine both the diagnostic and predictive value of flow variables derived 
from multiple recordings. 
 
Flow-volume nomograms  
Nomograms that allow for correction of flow rate for either the volume voided or the volume in the 
bladder are frequently presented and are produced from all urodynamic equipment.  However, the 
utility of these for diagnosis varies greatly and is never strong. These nomograms are unable to 
provide a urodynamic diagnosis but can indicate the probability of normality of maximum flow rate.  
The premise that inter-patient volume correction with these nomograms helps to establish better 
evaluation of treatment effect (on Qmax) has not been confirmed. 
Siroky
14
 produced a flow-volume nomogram from 80 male patients of unreported age, with bladder 
volume (not voided volume) on the vertical axis. Later, Kadow
15
 selected 123 older (between 50 and 
80 years) male patients, and formed a nomogram with slower flow rates than Siroky, but using voided 
volume alone.  The most comprehensive set of nomograms came from Haylen’s Liverpool study16, 
which produced nomograms from 331 male and 249 female patients of a wide age range. The 
Liverpool nomograms include, as did Siroky, graphs for both maximum and average flow rates, but 
also included a factor for age in the male equations and used voided volume. More recently, male
17 
(bladder volume) and female
18
 (voided volume) ‘PGIMER’ nomograms have been proposed for 
Indian populations, with factoring for the age of female patients. Additional proposals for male 
assessment have been made for individualised nomograms based on multiple flows
19
 and the D index 
from within the VBN modelling system
20
. 
The clinical perspective is that flow rate is a screening test and that normal flow rate can be used to 
exclude voiding abnormalities. Since the nomograms are all proposed for indicative, rather than 
diagnostic, use, they are limited in application to initial screening and indication of treatment 
outcome. Nevertheless the sensitivity, specificity, type of volume measured and influence of age and 
population type for each nomogram could be more clearly described and understood, otherwise 
unmerited diagnostic capacity may be assumed. 
Flow rate curve shape 
The terms used to describe the shape of the urine flow rate curve over time vary considerably.  In 
paediatric urology the analysis of uroflow pattern is standardized to a certain extent
21
, although 
anomalies exist, and shape can serve as a guide to the existence of a specific condition3,21, 22.  Since 
patient inhibition can occur during uroflowmetry, good technical performance of the test is critical, or 
dysfunction may be erroneously diagnosed on the basis of procedure faults or technical artefacts. 
Some of the terms to describe abnormally shaped flow curves may be regarded as confusing. For 
instance ‘staccato-shaped’ is used to describe an irregular, fluctuating curve and ‘interrupted-shaped’ 
to describe a curve with segments with zero flow
21, yet ‘staccato’ truly means ‘separated, detached’.  
Standard descriptions of uroflow curve in adults have other difficulties, for instance the descriptions 
‘constrictive’ and ‘compressive’ are used for different uroflow shapes23,.  Those labels are, however, 
describing the cause of the shape rather than the shapes themselves.  Consistency and clarity in 
description is therefore required, in order that a full analysis of the diagnostic utility of uroflow shape 
can be undertaken. 
Two research teams have used Qmax and Qave to diagnose urodynamic abnormality, and suggest 
relevance and applicability.
24, 25
 However the accuracy varies when trialled on different databases and 
the limitations have been discussed
26
.  A recent study
27
 has presented some mathematical analysis of 
uroflow curve shape, counting multiple peaks within filtered curves and considering the frequency 
content of the curve shape, but this has so far analysed only small numbers of patients and the 
specificity does not yet exceed that of the simple Qmax cut-off of 10 ml/s to select symptomatic men 
with a high likelihood of BOO. 
The current definition of dysfunctional voiding
22
 is confusing, referring as it does to irregular flowrate 
caused by inability to void and or by underactivity of the detrusor and / or by outlet smooth or striated 
muscle activity.  A container term as this is not helpful to ensure either optimum management or 
research to improve treatment for voiding difficulties. 
Uroflow time measurements 
ICS GUP defines flow time as “the time over which measurable flow actually occurs”23.  However, 
the threshold above which flow is considered “measurable” is not defined, and the equipment 
sensitivity will therefore affect the time value recorded.  The end of micturition is presumably 
considered to be at the end of measurable flow, but most urodynamic pressure flow studies will end 
with the patient giving a final cough, possibly resulting in measurable leakage which should not be 
regarded as part of the normal void.  A recent study proposed that 0.5 ml/s be used as the standard 
threshold for registering flow and that post-void leaks be ignored for the purpose of time recording
28
.  
Rollema
29
 reported that diagnosis of bladder outflow obstruction in men could be improved by 
considering the time from Qmax to the point where 95% of voided volume had been voided, but this 
parameter has never been confirmed and has not become standard. 
Other measurements alongside uroflow 
Flow lag time, defined as the time between pelvic muscle EMG decrease and urine flow beginning 
has been reported either to increase or to decrease as an effect of management of a variety of 
dysfunctional voiding types in children.
30
  However, standardisation of meatus to flowmeter distance 
(or of intravesical or voided volume) has not been carried out in these studies. Pelvic floor 
dysfunction as a cause for irregular voiding can be expected to be present in adults, although the 
evidence, e.g. from studies that report pelvic muscle EMG, is lacking
3
. 
Given that abdominal straining has variable effects on flow rate, it is reasonable to suggest that non-
invasive synchronous recording of abdominal pressure be investigated in different groups of patients.  
One study found that patients with detrusor underactivity are more likely to strain on voiding
31
, while 
another found that men with bladder outlet obstruction strained less
32
 which is understandable since a 
prostate receives just as much pressure increment as the bladder, as a consequence of its 
intraabdominal position, during abdominal pressure rises. 
Areas for research 
In view of the gaps in current knowledge detailed above, we recommend that studies be carried out to 
address the following research questions: 
 Can maximum flow rate be improved as a diagnostic criterion for adult women and young 
adult men? 
 Which definition of voiding dysfunction would be best applicable in clinical practice? 
 What signs and symptoms can be combined with uroflowmetry to enhance its diagnostic 
power? 
 Should an adult EMG – uroflowmetry test be designed? 
 Should an abdominal pressure – uroflowmetry test be designed? 
 How can the normalisation of flow rate to volume be improved, and nomograms consequently 
standardised? 
 How can urine flow curve shape analysis be standardized and quantified? 
 How can multiple flows and home uroflowmetry be applied to increase diagnostic accuracy?  
 How can thresholds and protocols for measuring urine flow time be more clearly defined? 
 
Conclusions 
The ICI-RS 2017 meeting has proposed a number of research questions that should be addressed to 
increase the diagnostic utility of non-invasive uroflowmetry.  There is scope for combining 
uroflowmetry with other non-invasive indicators, and for better standardisation of the test technique, 
flow-volume nomograms, uroflow shape descriptions and time measurements.  Given the ubiquity of 
the test, and its vulnerability to misunderstanding, there is a need for a consensus document on Good 
Practice for Uroflowmetry.  
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